Barclays Initiates Coverage of Insulet with Equal-Weight Rating
Fintel reports that on October 7, 2026, Barclays initiated coverage of Insulet (NASDAQGS:PODD) (LSE:0ADR) with a Equal-Weight recommendation. This initiation follows a prior action on May 8, 2026, when the firm maintained its Underweight rating on the stock.
Prior to this initiation, on October 6, 2026, Insulet's stock closed at $134.73. This latest close of $134.73 represents a price change of +1.42% over one week, relative to the baseline close of $132.84 on September 29, 2026. Over a one-month period, the stock has seen a price change of -8.65% from its baseline close of $147.48 on September 4, 2026.
As of October 2, 2026, the current consensus target mean for the stock is $185.65, with a median target of $175.95. This mean target represents an implied change of +37.80%. The prior consensus target mean was $185.65 as of September 15, 2026, indicating a consensus target revision of 0.00%.
Insulet reported its latest earnings on August 5, 2026, posting an actual EPS of 1.66 against an estimated EPS of 1.4795, which is a surprise of +12.20%. The company's actual revenue was $801,700,000.00, compared to the estimated revenue of $802,972,233.00. The company's upcoming earnings date is scheduled for November 4, 2026.
Regarding broader analyst sentiment, the current recommendation period as of September 1, 2026, includes 9 strong buy, 11 buy, and 13 hold recommendations, totaling 33. This translates to 60.6% positive recommendations and 39.4% hold recommendations. In the prior period starting August 1, 2026, the total of 33 recommendations consisted of 12 strong buy, 15 buy, and 6 hold recommendations, representing 81.8% positive recommendations and 18.2% hold recommendations.
Insulet Corporation, based in the United States, operates in the medical devices industry with a focus on diabetes management technology. Its main innovation is the Omnipod Insulin Management System, a tubeless insulin pump featuring a disposable pod component. The company aims to expand the system's technological capabilities andglobal marketreach through strategic partnerships and regulatory approvals, alongside integrated continuous glucose monitoring solutions.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 7, 2026 | Barclays | Equal-Weight | initiated coverage |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.